Cellectis competitors

Cellectis Competitors include Allogene Therapeutics, Biogen, MyoKardia and Athersys.
Add company...
Cellectis
Cellectis
Cellectis is a biopharmaceutical company focused on developing develop a new generation of cancer immunotherapies based on engineered allogeneic T-cells.
Allogene Therapeutics
Allogene Therapeutics
Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer.
Biogen
Biogen
Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.
MyoKardia
MyoKardia
MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.
Athersys
Athersys
Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.
Founding Date
Founding Date
1999
Founding Date
2018
Founding Date
1978
Founding Date
2012
Founding Date
1995
Type
Type
Public
Type
Public
Type
Public
Type
Public
Type
Public
Tags
Locations
Locations
Paris, FR HQ
New York, US
Locations
South San Francisco, US HQ
Locations
Cambridge, US HQ
Locations
South San Francisco, US HQ
Locations
Cleveland, US HQ
Canton, US
Employees
Employees
203
Employees
57
Employees
7,300
Employees
1024% increase
Employees
66
Valuation ($)
Valuation ($)
1.2 b
Valuation ($)
3.8 b
Valuation ($)
63.2 b
Valuation ($)
1.7 b
Valuation ($)
214 m
Twitter followers
Twitter followers
3.1 k
Twitter followers
N/A
Twitter followers
19.4 k
Twitter followers
387
Twitter followers
953

Financial

Revenue (est.)
Revenue (est.)
$33.7m (FY, 2017)
Revenue (est.)
N/A
Revenue (est.)
$11.4b (FY, 2016)
Revenue (est.)
$22.5m (FY, 2017)
Revenue (est.)
$3.7m (FY, 2017)
Net income
Net income
($103.7m) (FY, 2017)
Net income
N/A
Net income
$3.7b (FY, 2016)
Net income
($46m) (FY, 2017)
Net income
N/A

Operating

Patents (US)
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
N/A
Patents (US)
4 (FY, 2017)
Patents (US)
21 (FY, 2016)
Phase I Trials Products
Phase I Trials Products
N/A
Phase I Trials Products
N/A
Phase I Trials Products
4 (FY, 2016)
Phase I Trials Products
2 (FY, 2017)
Phase I Trials Products
N/A
Phase II Trials Products
Phase II Trials Products
N/A
Phase II Trials Products
N/A
Phase II Trials Products
10 (FY, 2016)
Phase II Trials Products
1 (FY, 2017)
Phase II Trials Products
N/A

Funding

Total funding raised
Total funding raised
$ 3.2m
Total funding raised
N/A
Total funding raised
N/A
Total funding raised
$ 98m
Total funding raised
$ 9m
For sources of this data, please see the company profileDownload Excel

View company profiles

Allogene Therapeutics
HQ
South San Francisco, US
Employees
57

Allogene Therapeutics is a clinical stage biotechnology company pioneering the development of allogeneic CAR T therapies for cancer.

View company
Biogen
HQ
Cambridge, US
Employees
7,300

Biogen develops, markets and manufactures therapies for people living with serious neurological, autoimmune and rare diseases.

View company
MyoKardia
HQ
South San Francisco, US
Employees
102↑ 4% increase

MyoKardia discovers, develops and commercializes targeted therapies for the treatment of serious and neglected rare cardiovascular diseases.

View company
Athersys
HQ
Cleveland, US
Employees
66

Athersys, a biopharmaceutical company, discovers and develops therapeutic products for the treatment of several disease indications.

View company